Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.59 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.53 |
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.53 |
| ▸ | CACNB1 | Q02641 | 6/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3866660 | 0.81 | CACNA2D1 (0.53) | CACNA1GOPRM1OPRD1CACNA2D1CACNB1 | |
| SCHEMBL5069064 | 0.79 | HPGD (0.58) | KCNA5HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL3869733 | 0.78 | DRD3 (0.62) | KCNA5CACNA1GMEN1KMT2ACACNA2D1 | |
| SCHEMBL16598604 | 0.78 | MEN1 (0.60) | KCNA5HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL16598603 | 0.78 | MEN1 (0.60) | KCNA5HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL5480294 | 0.77 | HPGD (0.61) | KCNA5HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL5080776 | 0.76 | ALOX5 (0.53) | CACNA1GHPGDCACNA2D1CACNB1CACNA1B | |
| SCHEMBL5080780 | 0.76 | CACNA2D1 (0.49) | CACNA1GCACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL3890903 | 0.76 | CACNA2D1 (0.64) | KCNA5CACNA1GMEN1KMT2AALDH1A1 | |
| SCHEMBL3871235 | 0.76 | CACNA2D1 (0.60) | KCNA5CACNA1GCACNA2D1CACNB1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | claimed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | claimed |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-12-04 | — | — | US | disclosed |
| EP-1871372-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | disclosed |
| WO-2006105670-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | KCNA5 92/4885CACNA1G 4/4885HPGD 2178/4885 |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | CACNA1B, TRPV1, ORAI1 | KCNA5 229/4885CACNA1G 13/4885HPGD 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.